other material
confidence high
sentiment neutral
materiality 0.50
Stockholders approve 1.52M share increase in 2023 Equity Incentive Plan at annual meeting
VYNE Therapeutics Inc.
- Increase of 1,520,000 shares to 2023 Plan; total reserve now 1,651,907 shares.
- Eliminated 'liberal' share recycling for stock options and SARs.
- Incentive stock option limit raised to 3,619,586 shares.
- David Domzalski and Patrick LePore re-elected as Class III directors.
- Baker Tilly ratified as auditor; say-on-pay approved; advisory vote set for every year.